Redefining the refined retroperitoneal lymph node dissection in testis cancer: a SWOT analysis of nonrandomized data.
Garnick
Marc B
MB
D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D006801:Humans; D015994:Incidence; D008197:Lymph Node Excision / Q000379:methods*; D008297:Male; D018365:Neoplasm, Residual / Q000453:epidemiology* / Q000473:pathology; D009373:Neoplasms, Germ Cell and Embryonal / Q000453:epidemiology / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D012186:Retroperitoneal Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D012187:Retroperitoneal Space; D012735:Sexual Dysfunction, Physiological / Q000517:prevention & control; D013736:Testicular Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D014481:United States / Q000453:epidemiology
D000970:Antineoplastic Agents